CANSINOBIO Initiates Phase I/II Trial of 24-Valent Pneumococcal Conjugate Vaccine PCV24, Enrolls First Patient

Bulletin Express

05/26

CanSino Biologics Inc. (CANSINOBIO) has commenced a Phase I/II clinical study for its 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT), PCV24, and recorded the first patient enrollment.

The trial, formally launched after National Medical Products Administration approval in January 2026, will assess safety and immunogenicity in participants aged six weeks and older. PCV24 targets 24 circulating pneumococcal serotypes and leverages covalent conjugation of polysaccharide antigens to dual protein carriers (CRM197 and tetanus toxoid).

PCV24 expands CANSINOBIO’s pneumococcal portfolio, following the June 2025 Chinese market approval of its 13-valent product, iPneucia. No 24-valent pneumococcal conjugate vaccine is currently available worldwide, positioning PCV24 as a potential first-in-class entrant.

The company cautions shareholders and prospective investors to exercise prudent judgment when trading its shares.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1149227006"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1149227006\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1149227006?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-26 08:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1149227006","market":"hk","top_or_hot":-1,"title":"CANSINOBIO Initiates Phase I/II Trial of 24-Valent Pneumococcal Conjugate Vaccine PCV24, Enrolls First Patient","media":"Bulletin Express","content":"<p>CanSino Biologics Inc. (CANSINOBIO) has commenced a Phase I/II clinical study for its 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT), PCV24, and recorded the first patient enrollment.</p>\n<p>The trial, formally launched after National Medical Products Administration approval in January 2026, will assess safety and immunogenicity in participants aged six weeks and older. PCV24 targets 24 circulating pneumococcal serotypes and leverages covalent conjugation of polysaccharide antigens to dual protein carriers (CRM197 and tetanus toxoid).</p>\n<p>PCV24 expands CANSINOBIO’s pneumococcal portfolio, following the June 2025 Chinese market approval of its 13-valent product, iPneucia. No 24-valent pneumococcal conjugate vaccine is currently available worldwide, positioning PCV24 as a potential first-in-class entrant.</p>\n<p>The company cautions shareholders and prospective investors to exercise prudent judgment when trading its shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CANSINOBIO Initiates Phase I/II Trial of 24-Valent Pneumococcal Conjugate Vaccine PCV24, Enrolls First Patient</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCANSINOBIO Initiates Phase I/II Trial of 24-Valent Pneumococcal Conjugate Vaccine PCV24, Enrolls First Patient\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-05-26 08:25</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>CanSino Biologics Inc. (CANSINOBIO) has commenced a Phase I/II clinical study for its 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT), PCV24, and recorded the first patient enrollment.</p>\n<p>The trial, formally launched after National Medical Products Administration approval in January 2026, will assess safety and immunogenicity in participants aged six weeks and older. PCV24 targets 24 circulating pneumococcal serotypes and leverages covalent conjugation of polysaccharide antigens to dual protein carriers (CRM197 and tetanus toxoid).</p>\n<p>PCV24 expands CANSINOBIO’s pneumococcal portfolio, following the June 2025 Chinese market approval of its 13-valent product, iPneucia. No 24-valent pneumococcal conjugate vaccine is currently available worldwide, positioning PCV24 as a potential first-in-class entrant.</p>\n<p>The company cautions shareholders and prospective investors to exercise prudent judgment when trading its shares.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06185","symbol_name":"康希諾生物","start_time":0,"source_url":"","article_id":"1149227006","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1149227006","pubTimestamp":1779755154,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CanSino Biologics Inc. (CANSINOBIO) has commenced a Phase I/II clinical study for its 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT), PCV24, and recorded the first patient...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06185":"康希诺生物"},"translate_title":"康希诺生物启动24价肺炎球菌结合疫苗PCV24 I/II期试验，入组首例患者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06185":1},"content_text":"CanSino Biologics Inc. (CANSINOBIO) has commenced a Phase I/II clinical study for its 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT), PCV24, and recorded the first patient enrollment.\nThe trial, formally launched after National Medical Products Administration approval in January 2026, will assess safety and immunogenicity in participants aged six weeks and older. PCV24 targets 24 circulating pneumococcal serotypes and leverages covalent conjugation of polysaccharide antigens to dual protein carriers (CRM197 and tetanus toxoid).\nPCV24 expands CANSINOBIO’s pneumococcal portfolio, following the June 2025 Chinese market approval of its 13-valent product, iPneucia. No 24-valent pneumococcal conjugate vaccine is currently available worldwide, positioning PCV24 as a potential first-in-class entrant.\nThe company cautions shareholders and prospective investors to exercise prudent judgment when trading its shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}